Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Epizyme, Inc. (EPZM)

1.47   0 (0%) 12-31 19:00
Open: 1.49 Pre. Close: 1.47
High: 1.4993 Low: 1.47
Volume: 0 Market Cap: 0(M)

Technical analysis

as of: 2022-11-18 4:20:17 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 1.73     One year: 1.75
Support: Support1: 1.47    Support2: 1.22
Resistance: Resistance1: 1.48    Resistance2: 1.49
Pivot: 1.47
Moving Average: MA(5): 1.47     MA(20): 1.47
MA(100): 1.47     MA(250): 1.47
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 0     %D(3): 0
RSI: RSI(14): 60.7
52-week: High: 3.59  Low: 0.41
Average Vol(K): 3-Month: 0 (K)  10-Days: 0 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EPZM ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.5 - 1.51 1.51 - 1.52
Low: 1.45 - 1.46 1.46 - 1.47
Close: 1.46 - 1.47 1.47 - 1.48

Company Description

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

Headline News

Wed, 27 Sep 2023
Company Announcement - InvestEgate

Fri, 12 Aug 2022
Ipsen completes acquisition of Epizyme expanding its portfolio in ... - Ipsen

Fri, 05 Aug 2022
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 ... - Ipsen

Mon, 27 Jun 2022
Ipsen to acquire Epizyme, expanding its portfolio in oncology - Ipsen

Thu, 02 Jun 2022
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 ... - Business Wire

Tue, 10 May 2022
Epizyme Reports First Quarter 2022 Financial Results and Provides ... - Business Wire

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 104 (M)
Shares Float 133 (M)
% Held by Insiders 0.5 (%)
% Held by Institutions 90.3 (%)
Shares Short 5,490 (K)
Shares Short P.Month 10,390 (K)

Stock Financials

EPS -2.3
EPS Est Next Qtl -0.68
EPS Est This Year -2.36
EPS Est Next Year -2.45
Book Value (p.s.) 1.46
Profit Margin (%) 0
Operating Margin (%) -582.2
Return on Assets (ttm) -39
Return on Equity (ttm) -352.4
Qtrly Rev. Growth 14
Gross Profit (p.s.) 0.17
Sales Per Share 0.37
EBITDA (p.s.) -2.11
Qtrly Earnings Growth 0
Operating Cash Flow -210 (M)
Levered Free Cash Flow -112 (M)

Stock Valuations

PE Ratio -0.65
PEG Ratio -0.1
Price to Book value 1
Price to Sales 3.96
Price to Cash Flow -0.73

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.